Approval · Notice of Compliance 36715 · 2026
TAKHZYRO: Notice of Compliance 36715
Issued January 9, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36715
- Date
- January 9, 2026
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New presentation. Updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TAKHZYRO | Not yet assigned | — |
| TAKHZYRO | 02564483 | Marketed |
Medicinal ingredients
- LANADELUMAB 300 MG per 2ML
- LANADELUMAB 300 MG per VIAL